UNSPSC 51263103: Adimolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C25H29N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B6CJY5K2ST, chemically known as (rs)-2,3-dihydro-1-(3-(2-hydroxy-3-(naphthyloxy)propylamino)-3-methylbutyl)-1h-2-benzimidazolon but generally known as adimolol, which bears US NIH Compound Identifier 71227. Adimolol most often comes in forms base, hydrochloride, and hydrate.

UNSPSC 51263103 Adimolol, a Commodity code, nominally addresses a specific pharmaceutical ingredient, but recent state and local opportunities tagged under this code do not reflect pharmaceutical procurement in the traditional sense. Instead, the code has been applied to emergency response and pharmacy benefit program initiatives that center on naloxone distribution, drug deactivation systems, and direct-to-manufacturer prescription fulfillment models. The actual buying activity under this code encompasses public health emergency supplies—naloxone and drug deactivation systems procured for community health support—and strategic pharmacy benefit management restructuring. Issuing bodies include county health departments and state health and human services agencies pursuing these initiatives independently.

Recent activity appears concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with a response deadline of July 26, 2023, and quarterly deliveries required to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs aimed at improving fulfillment efficiency and cost management outside traditional pharmacy benefit manager and group purchasing organization channels. The Texas inquiry emphasizes vendors' experience with direct contracting for self-insured employers and value-based or outcomes-based agreements. Neither opportunity specifies explicit set-asides for disadvantaged enterprises, and both require vendors to meet standard federal compliance expectations including E-Verify eligibility confirmation and drug-free workplace certification where applicable.